Trial Profile
Molecular profiling of post-menopausal women with breast cancer on neoadjuvant endocrine therapy with tamoxifen or exemestane.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MoNET
- 24 Feb 2011 Planned end date changed from 1 Jan 2010 to 1 May 2011 as reported by ISRCTN: Current Controlled Trials.
- 22 Feb 2011 Status changed from recruiting to completed, as reported by Current Controlled Trials.
- 20 Apr 2007 New trial record.